by Ashley Davis | Jul 23, 2019 | Publications and Articles
Classical analyses of pharmaceutical pipelines from 1990 to 2010 reported increasing attrition rates and duration of clinical trials, leading to a perception of a “productivity crisis” in this sector. However, in contrast, a more recent analysis of over 45,000...
by Ashley Davis | Jun 27, 2019 | Publications and Articles
Computer-based virtual reality assessments of functional capacity have shown promise as a reliable and valid way to assess individuals with multi-episode schizophrenia. However, there has been little research utilizing this innovative approach with young patients who...
by Ashley Davis | Jun 25, 2019 | Case Study
How VeraSci supported authentic translation and cultural adaptation of neurocognitive assessments in a multinational, large scale, long-term clinical trial for delaying the onset of Mild Cognitive Impairment stage of Alzheimer’s Disease.
by Ashley Davis | Jun 20, 2019 | Publications and Articles
The Schizophrenia Cognition Rating Scale (SCoRS) is a 20-item interview-based clinical assessment that evaluates cognitive deficits and the degree to which these deficits impair patients’ day-to-day functioning. It was originally developed in 2001 at Duke University...
by Ashley Davis | Jun 13, 2019 | Press Releases
VeraSci, a leading provider of innovative scientific and technology services, announced today the hire of Hampton Corley, Chief Commercial Officer, to support growth objectives. As clinical trials grow in scope and complexity, VeraSci provides the scientific and...
